European shares were at a record high on Friday, led by technology and healthcare stocks, even as caution prevailed ahead of ...

Jefferies analyst Peter Welford maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

Novartis AG said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug, ...

Novartis expects profit and sales to grow further this year after beating analysts' expectations in the fourth quarter, boosted by revenue from its key drugs.

Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...

Swiss drug major Novartis AG (NVS) reported Friday that its fourth-quarter net income plunged to $2.82 billion from last year's $8.48 ...

The Bureau of Economic Analysis will release the personal consumption expenditures, or PCE, price index for December on Friday at 8:30 a.m. ET, as part of its personal income and outlays report. Gold ...

Japan is considering offering support for a $44 billion gas pipeline in Alaska as it seeks to court U.S. President Donald ...

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

Coherus BioSciences, Inc.’s CHRS share price has surged by 10.66%, which has investors questioning if this is right time to sell.